SEC Form 4 · accession 0001193125-26-354201
Kura Oncology, Inc. · KURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Troy Edward Wilson
Officer — President and CEO · Director
Period of report
Aug 17, 2026
Accepted (ET)
Aug 17, 2026 · 4:45 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001422143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 17, 2026 | P | 100,000 | $11.12 | A | 379,194 | I | by One Fish Two Fish Revocable Trust |
| Common Stock | holding | — | — | — | 300,000 | I | by Lorax Charitable Remainder Unitrust | |
| Common Stock | holding | — | — | — | 435,456 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $10.87 to $11.31. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.